- DINAMIQS, a Siegfried company, has inaugurated a 2,500m² cGMP facility in Zurich for viral vector gene therapy manufacturing, supporting R&D, clinical, and commercial supply.
- The company announced a strategic collaboration with SEAL Therapeutics to scale production of a gene therapy for severe LAMA2-related muscular dystrophy.
DINAMIQS, a Siegfried company, has opened a new state-of-the-art cGMP manufacturing facility for viral vectors in Zurich, Switzerland. The facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling, with production capacity up to 1,000 litres.
The 2,500m² site brings R&D, clinical, and commercial manufacturing under one roof. Its modular, segregated design with closed, single-use technologies ensures GMP compliance, strict containment, and faster turnaround times. Lab space at the facility has been operational since Q3 2024.
Alongside the facility inauguration, DINAMIQS announced a strategic collaboration with SEAL Therapeutics, a spin-off from the University of Basel. The partnership will support the development and scale-up of a gene therapy targeting LAMA2-related muscular dystrophy, a severe childhood-onset disease currently without treatment options.
“Since acquiring the startup in 2023, Siegfried’s ambition has been to bring DINAMIQS’ capabilities to commercial scale and establish it as a leading CDMO in the cell and gene therapy space. With the opening of the new manufacturing facility and growing customer demand, we are well on track to achieving this goal.”
Marcel Imwinkelried, CEO of Siegfried
DINAMIQS aims to provide clients with a single partner for lead optimisation, R&D production, and clinical and commercial supply. This approach is designed to reduce time and cost for developers of cell and gene therapies while accelerating patient access.
